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Cardiac proton spectroscopy (1H-MRS) is widely used to quantify lipids. Other metab-
olites (e.g. creatine and choline) are clinically relevant but more challenging to quan-
tify because of their low concentrations (approximately 10 mmol/L) and because of
cardiac motion. To quantify cardiac creatine and choline, we added water-
suppression cycling (WSC) to two single-voxel spectroscopy sequences (STEAM and
PRESS). WSC introduces controlled residual water signals that alternate between
positive and negative phases from transient to transient, enabling robust phase and
frequency correction. Moreover, a particular weighted sum of transients eliminates
residual water signals without baseline distortion. We compared WSC and the ven-
dor's standard ‘WET’ water suppression in phantoms. Next, we tested repeatability
in 10 volunteers (seven males, three females; age 29.3 ± 4.0 years; body mass index
[BMI] 23.7 ± 4.1 kg/m2). Fat fraction, creatine concentration and choline concentra-
tion when quantified by STEAM-WET were 0.30% ± 0.11%, 29.6 ± 7.0 μmol/g and
7.9 ± 6.7 μmol/g, respectively; and when quantified by PRESS-WSC they were
0.30% ± 0.15%, 31.5 ± 3.1 μmol/g and 8.3 ± 4.4 μmol/g, respectively. Compared with
STEAM-WET, PRESS-WSC gave spectra whose fitting quality expressed by Cramér-
Rao lower bounds improved by 26% for creatine and 32% for choline. Repeatability
of metabolite concentration measurements improved by 72% for creatine and 40%
for choline. We also compared STEAM-WET and PRESS-WSC in 13 patients with
severe symptomatic aortic or mitral stenosis indicated for valve replacement surgery
(10 males, three females; age 75.9 ± 6.3 years; BMI 27.4 ± 4.3 kg/m2). Spectra were
of analysable quality in eight patients for STEAM-WET, and in nine for PRESS-WSC.
We observed comparable lipid concentrations with those in healthy volunteers, sig-
nificantly reduced creatine concentrations, and a trend towards decreased choline
Abbreviations used: ADP, adenosine diphosphate;; ATP, adenosine triphosphate; Cho, choline; CK, creatine kinase; Cr, creatine; CRLB, Cramér-Rao lower bounds; HLSVD, Hankel–Lanczos
singular value decomposition; MAD, median absolute deviations; OXSA, Oxford Spectroscopy Analysis (open-source MATLAB toolbox); PCr, phosphocreatine; Pi, inorganic phosphate; PRESS,
Point RESolved Spectroscopy; STEAM, STimulated Echo Acquisition Mode; WET, water suppression enhanced through T1 effects; WSC, water-suppression cycling.
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concentrations. We conclude that PRESS-WSC offers improved performance and
reproducibility for the quantification of cardiac lipids, creatine and choline concentra-
tions in healthy volunteers at 3 T. It also offers improved performance compared with
STEAM-WET for detecting altered creatine and choline concentrations in patients
with valve disease.
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1 | INTRODUCTION
Magnetic resonance spectroscopy (1H-MRS) is an established method to assess metabolite concentrations in the human heart. In diseases such as
obesity and type 2 diabetes, the heart's uptake and oxidation of fatty acids are not balanced, resulting in an accumulation of triglycerides.1 The
accumulation of triglycerides leads to metabolic derangement, which has been proposed as a contributory and/or perpetuating factor in non-
ischaemic cardiomyopathies.1,2 Therefore, most published cardiac 1H-MRS studies have focused on quantifying lipid concentrations.3–5 However,
with sufficient data quality, 1H-MRS can also assess lower concentration metabolites such as creatine (Cr) and choline* (Cho) that are of high clini-
cal interest.6–8
Cr is an important component in the creatine kinase (CK) enzyme system.9 CK catalyses the transfer of a high-energy phosphate group from
adenosine triphosphate (ATP) onto Cr to form phosphocreatine (PCr) and adenosine diphosphate (ADP) in the mitochondria:
ATP+ freeCr ⇌ ADP+PCr: ð1Þ
In the myofibrils, the reverse reaction provides a very rapid supply of ATP to meet demand during bursts of effort such as sustaining contrac-
tion throughout systole.10,11 These ATP-delivery processes become deranged in heart failure, according to the energy-starvation hypothesis.12 In
failing human and animal hearts, free Cr and PCr concentrations drop substantially soon after disease onset13 and before failure of ATP homeo-
stasis.9,14 Note that, in vivo, the free Cr and PCr 1H-MRS peaks are overlapping. It is therefore common to report ‘total creatine’ (tCr), defined as
the sum of free Cr and PCr. Cr concentrations obtained via 1H-MRS can be used to calculate the heart's energy reserve (jΔGATPj),15,16 which in
turn can predict isovolumic contractile reserve17 and peak cardiac work.18,19 Hence, a decrease in jΔGATPj limits the heart's maximum mechanical
work and, eventually, a reduced jΔGATP j could lead to heart failure. On top of that, jΔGATPj is a potential biomarker that could be used to evaluate
novel ‘energy-sparing’ treatments for heart failure, for example, drugs that modulate fatty acid oxidation, such as etomoxir20 and perhexiline.21
Cholines are a class of quaternary ammonium salts that serve several physiological functions such as maintaining structural integrity in cell
membranes and facilitating cell membrane signalling.22 The Cho derivative acetylcholine is an important neurotransmitter in the autonomic ner-
vous system, which regulates heart rate and blood pressure,23 and in the brain, where defective cholinergic signalling is implicated in Alzheimer's
dementia.24 Cholines have also been identified as a potential biomarker for identifying active tumours, for example, in the brain,25 breast26 and
liver.27 However, whether myocardial choline levels change in disease is still poorly understood in both animal models and humans.
To date, most in vivo cardiac 1H-MRS studies have used single-voxel spectroscopy (SVS) techniques such as STimulated Echo Acquisition Mode
(STEAM) and Point RESolved Spectroscopy (PRESS) together with a pulse sequence module that suppresses water signals.28 Patient motion,
including respiration and cardiac motion, mean that there can be phase and frequency shifts between each transient recorded by the scanner. This
can cause incoherent averaging during postprocessing, and hence reduce signal-to-noise ratio (SNR). A common approach for both cardiac and brain
spectroscopy involves phasing and frequency shifting individual transients using the largest peak (residual water or a metabolite).3,28–32 To ensure
that there is a sufficiently large reference peak for frequency and phase correction, many studies only partially suppress water (so-called ‘weak water
suppression’).28,29 However, with weak water suppression, the residual water peak can still cause problems during spectral fitting.33
In this work, we propose instead to use a water-suppression cycling (WSC) method,34 originally developed for brain 1H-MRS, to improve the
quality of cardiac single-voxel 1H-MRS at 3 T. The WSC technique inserts a weak water suppression module and adds an inversion pulse in alter-
nate transients. The weak water suppression property of this module provides a high SNR residual water peak for frequency and phase correction,
while inverting the residual water signal every other scan allows for practically complete elimination of the residual water peak during post-
processing (as we show below), which improves spectral fitting (e.g. by avoiding errors from baseline distortion). WSC is similar conceptually to
the method known as ‘metabolite cycling’,7,35 except that during metabolite cycling it is the metabolite peaks that are inverted, whereas WSC
only inverts the residual water peak.
Here, we aimed to test the feasibility of the WSC approach to improve quantification of low-concentration metabolites such as Cr and Cho
(as well as lipids) in the heart at 3 T; and to investigate potential changes in cardiac Cr and Cho levels in patients with valvular stenosis.
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This is a particularly exciting, but as of yet underinvestigated group of patients, in which 15% of patients undergoing surgical aortic valve
replacement have reduced left ventricular ejection fraction (LVEF; <50%).36–38However, at present it is not possible to anticipate or explain why
the myocardium in some patients, but not others, exhibits contractile decline in the face of sustained severe pressure overload. Nonetheless, oth-
erwise unexplained contractile decline into the borderline (LVEF 50%–59%) range worsens prognosis38–40 and, in the absence of good under-
standing regarding the underlying mechanism, there is currently no specific medical therapy other than to refer patients for timely valve
replacement once the valve disease has progressed into the severe range. The metabolic hypothesis of heart failure posits that reduced metabolic
reserve is both a permissive and a causative factor at play, and while there are many animal models that support this,41,42 the evidence in human
pressure overload hypertrophy is sparser13,43 because of the difficulty in obtaining human myocardium, and also because there are few
established techniques for noninvasive myocardial metabolic phenotyping. Despite the known association between reduced PCr/ATP ratio and
pathological left ventricular hypertrophy, there is mixed evidence regarding whether tCr itself is reduced in this setting,43–47 yet this would be a
key variable to establish if one is to estimate the concentration of free ADP from the CK equilibrium expression and thereby come to an estimate
of the free energy of ATP hydrolysis.
2 | THEORY
2.1 | Water-suppression cycling
The water-suppression cycling (WSC) module was first implemented by Ernst and Li for 1H-MRS in the brain.34 This technique alternates between
positive and negative residual water signal every other transient. The residual water signal can be used to correct for phase and frequency shifts
in single shots and its alternating phase allows for the elimination of the water peak upon postprocessing.
The implementation of the pulse sequence and the postprocessing of each transient is presented in Figure 1. WSC is an interleaved method.
The WSC module comprises four chemical shift selective RF pulses spaced 50 ms apart for partial water suppression prior to a standard single-
voxel pulse sequence such as PRESS or STEAM. Each RF pulse is a Gaussian with a time-bandwidth product of 0.896 centred on water, and the
spoiler gradients between pulses suppress residual transverse magnetisation (Mxy).
34 The third pulse in the module, a 180 chemical shift selective
inversion pulse, is activated in odd-numbered acquisitions and disabled in even-numbered acquisitions, yielding two different spectra, Sodd and
Seven. This alternation results in the residual water and metabolite peaks having the same phases in Sodd and opposite phases in Seven.
Three corrections were applied before the odd- and even-numbered acquisitions were averaged together. First, frequency correction was
performed to correct for minor frequency differences between the water signals in each transient. Second, a zero-order phase correction was
performed based on the phase of the residual water peak to make it positive real in even transients and negative real in odd transients. Third,
a weighting factor w, which compensates for T1 relaxation of the water signal and imperfections in the inversion pulses, was determined by
least-squares fitting, such that spectra summed according to Equation 2 have minimum residual water signal. Finally, the odd and even






In many ways, the WSC approach is similar to the method of metabolite cycling.35 However, WSC has potential advantages, such as the residual
water peak is eliminated before spectral fitting, and that because the metabolites are not inverted, WSC may be less sensitive to the T1 values of
metabolites and the efficiency of the inversion pulse, as shown in Ernst and Li0s original study.34
3 | METHODS
All data were collected using a whole-body clinical 3 T Prisma MRI scanner (Siemens Healthineers, Erlangen, Germany) with an 18-channel cardiac
receive array coil (Siemens Healthineers) and a 32-channel spine receive array coil (Siemens Healthineers).
3.1 | 1H MRS sequence
We compared the vendor's standard ‘water suppression enhanced through T1 effects’ (WET)48 water-suppression module against the WSC mod-
ule described above. This gave four different protocols:
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F IGURE 1 Explanation of the water-suppression cycling (WSC) 1H-MRS approach. A, Simplified pulse diagram showing the difference in
water suppression between odd- and even-numbered transients. B, Top: frequency domain plots of simulated example odd and even transients;
bottom: the average of these; inset: zoom to show metabolite signal amplitudes. C, Equivalent plots after per-transient frequency and phase
correction based on the residual water peak. D, Equivalent plots with per-transient frequency and phase correction and weighting according to
Equation 2. The final WSC spectrum is shown at the bottom right. Note that a green dashed line is plotted at the same vertical position in all
three columns to illustrate that the WSC processing preserves metabolite peak amplitudes





To minimise the loss of signal due to T2 decay, we also modified the gradient slew rates and amplitudes to achieve shorter echo times for all
four sequences (26 ms for PRESS and 10 ms for STEAM). On top of that, to improve performance of the vendor's WET water suppression for
in vivo scans, we followed the procedure of Rial et al.3 and used an additional breath-held prescan to manually optimise the water-suppression flip
angles.
3.2 | Data acquisition
3.2.1 | Phantom study
A phantom study was conducted to validate the ability to quantify Cr concentrations for each sequence together with its postprocessing steps in
the absence of motion. A six-compartment phantom was prepared in a silicone ice-cube tray with varying concentrations of Cr (Figure S2). The
following were added to each compartment: agar (Sigma-Aldrich; 2.3% w/w), NaCl (Sigma-Aldrich; 43 mmol/L), sodium dodecyl sulphate (Sigma-
Aldrich; 43 mmol/L), NiCl2 (Sigma-Aldrich; 0.89 mmol/L), peanut oil (Tesco, UK; 1% v/v) and Cr (Sigma-Aldrich; 0, 5, 10, 20, 40 and 80 mmol/L).
The mixture was heated to boiling point until the agar dissolved completely and the solution turned clear (after around 30 min), and was then left
to set overnight.
Spectra were acquired from the phantom from a 20 × 20 × 20 mm3 voxel in the centre of each compartment after B0 shimming with the ven-
dor's ‘standard’ method over an adjustment volume of 40 × 40 × 40 mm3. For each compartment, 30 individual water-suppressed and three
nonwater-suppressed measurements (i.e. shots) were obtained with STEAM and PRESS using the product WET water suppression and product
WET calibration, and then again using WSC water suppression (i.e. all four combinations). For nonwater-suppressed acquisitions, only the gradi-
ents were active in the water-suppression module (WSC or WET), and not the RF pulses. The acquisition parameters were 1024 points, 2 kHz
bandwidth, 4 s TR, 10 ms TE for STEAM and 26 ms TE for PRESS, and 50 Hz water suppression pulse bandwidth. The scanner centre frequency
was set at water (4.7 ppm) for nonwater-suppressed acquisitions and the methyl group in Cr (3.0 ppm) for water-suppressed acquisitions.
3.2.2 | Reproducibility study in healthy volunteers
Ten healthy volunteers (seven males, three females; mean age ± standard deviation [SD] = 29.3 ± 4.0 [range 23–34] years; body mass index [BMI]
= 23.7 ± 4.1 kg/m2) were recruited for this study and gave informed consent in accordance with local board ethics regulations.
For each session, the volunteers were positioned head-first supine in the scanner with ECG gating (Siemens). Cine images were used to obtain
horizontal long-axis and short-axis views of the heart. The MRS voxel was placed in the midinterventricular septum, to minimise the chance of
contamination from epicardial fat. The trigger delay was adjusted for mid-diastole, where cardiac motion is minimised,49 usually around 650 ms
for an average R-R interval of 1000 ms. B0 shimming with the vendor's ‘heart’ method was performed over an adjustment volume of
40 × 32 × 30 mm3 during a breath-hold. 1H-MRS data were obtained at end-expiration from a 32 × 26 × 22 mm3 voxel centred on the septum
(Figure 2). This voxel contains more ventricular blood compared with previous studies that used smaller voxels (2–8 cm3),50–56 but both STEAM
and PRESS have been demonstrated to have dark blood properties,3,50,51 so contamination from the blood pool should not be significant.57
Due to institutional limits on scan durations and the challenge of repeated breath-holds, it was not possible to run all four sequences. An ini-
tial experiment was conducted with six healthy volunteers (three males, three females; age = 32.5 ± 6.2 [range 25–42] years;
BMI = 23.1 ± 1.97 kg/m2) to compare PRESS-WET (150 measurements over 30 breath-holds) with STEAM-WET (150 measurements over
30 breath-holds). On the basis of this preliminary study, PRESS-WET was excluded from the later in vivo comparison (see Figure S2 for spectra
and Table S1 for SNR, Cramér-Rao lower bounds [CRLB] and linewidths for the preliminary study). Thus, in the main study, three sequences were
run on the volunteers: STEAM-WET, STEAM-WSC and PRESS-WSC. Parameters for all three sequences matched the phantom experiment, with
the following changes: 2 s TR for water-suppressed acquisitions and the water-suppression bandwidth for the WSC module was set at 65 Hz. For
STEAM-WET, 150 water-suppressed spectra were acquired over 30 breath-holds and three nonwater-suppressed spectra were acquired over
one breath-hold to give a high-quality ‘reference’ dataset.
For STEAM-WSC and PRESS-WSC, 60 water-suppression cycled spectra (i.e. 30 pairs) were acquired over 10 breath-holds and three water-
nonsuppressed spectra were acquired over one breath-hold. Across all sequences, each breath-hold was 11–13 s long, and a 13–20 s pause was
given between each breath-hold. Each session took around 1 h in total.
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To obtain repeatability data, each volunteer was scanned in two different sessions on the same day. They were taken out of the scanner
between sessions, given a 5-min break, and then the scan protocol was repeated. The total scan time for each volunteer was just over 2 h includ-
ing the repeat session. However, the large number of breath-holds and long scan times were challenging for some volunteers. Based on an interim
analysis of data from the first session in the first three volunteers, the STEAM-WSC was not repeated in the second session for the remaining
volunteers.
3.2.3 | In vivo study in patients
Thirteen patients (10 males, three females; age = 75.9 ± 6.3 [range 63–83] years; BMI = 27.4 ± 4.3 kg/m2) with severe symptomatic aortic or
mitral stenosis were recruited as part of a project approved by regional (South Central Oxford C, 16/SC/0323) and local ethics and governance
panels. Out of the group, eight patients had aortic stenosis with preserved LVEF, three had aortic stenosis with reduced ejection fraction and one
had mitral stenosis. The inclusion criteria were age 18–85 years, with severe aortic stenosis and due to undergo clinically indicated aortic valve
replacement, or no pressure- or volume-loading valve disease (i.e. no hypertrophy) but due to undergo cardiac surgery and willing to donate car-
diac biopsy. The exclusion criteria were prior myocardial infarction, flow-limiting coronary disease, more than mild bystander valve disease, renal
impairment (estimated glomerular filtration rate < 30 mL/min), or contraindication to MRI scanning. A table summarising the patient demographics
is included in the supporting information (Table S2).
F IGURE 2 Voxel position (white box) as shown on a short-axis view (left) and a horizontal long axis view (right)
TABLE 1 Metabolite concentrations and fat fractions (mean ± SD over all n subjects) are shown in, with the number of outliers in each
dataset denoted by the number of ‘+’ in brackets, that is, (+) means one outlier, (++) means two outliers, etc. Any statistically significant changes in
metabolite concentration between healthy volunteers and patients as measured by a particular sequence is indicated by * (when p < 0.05) or **
(when p < 0.01)
Mean ± standard deviation of metabolite concentration
Group Sequence Meas. Lipid (%) Creatine (μmol/g) Choline (μmol/g)
Healthy n = 10 STEAM-WET-150 150 0.30 ± 0.15 (+) 29.6 ± 7.0 (++) * 7.9 ± 6.7
PRESS-WSC 60 0.30 ± 0.11 (+) 31.5 ± 3.1 (+) ** 8.3 ± 4.4 (+) *
Patients n = 8 STEAM-WET-150 150 0.48 ± 0.51 (+) 8.0 ± 2.3 (+) * 4.6 ± 3.2
PRESS-WSC 60 0.25 ± 0.19 (+) 9.3 ± 6.0 ** 3.9 ± 3.2 *
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For each patient, 150 measurements (30 breath-holds) were obtained with the STEAM-WET sequence as the STEAM-WET-150 reference
dataset and 60 measurements (10 breath-holds) were obtained with the PRESS-WSC sequence.
3.3 | Data analysis
3.3.1 | Data postprocessing
Signals from individual coil elements for each shot were combined and averaged using MATLAB (Mathworks, Natick, MA, USA). Weighting and
phase-correction factors for each coil were calculated from the water peak in the nonwater-suppressed spectra and applied to the water-
suppressed spectra.3,58
The spectrum from each transient was phase- and frequency-corrected based on either the lipid peak (for STEAM-WET and PRESS-WET) or
the residual water peak (STEAM-WSC and PRESS-WSC) before averaging. A more detailed explanation of the postprocessing steps for WSC
sequences can be found in the Theory section and in Figure 1. All spectra were analysed using the OXSA toolbox.59 For the Cr-fat phantom, five
Lorentzian peaks were fitted: residual water around 4.7 ppm, Cr CH2 peak around 3.9 ppm, Cr CH3 peak around 3.0 ppm and two lipid peaks
around 1.28 and 0.84 ppm. For in vivo WET water-suppressed spectra, residual water signals were removed by the Hankel–Lanczos singular value
decomposition (HLSVD) method.60,61 The resulting spectra were fitted with seven peaks: residual water, two peaks for the methyl and methylene
group of tCr at 3.0 and 3.9 ppm; a peak for the methyl group of Cho derivatives at 3.2 ppm; and three peaks for lipids chains at 1.99 ppm (allylic),
1.28 ppm (methylene) and 0.84 ppm (methyl).4 Note that although we fit two peaks for Cr, we used only the Cr CH3 signal at 3.0 ppm for analysis
of tCr. In this paper, we use ‘choline’ to refer to any trimethylammonium (TMA) compound, as used by Gillinder et al.6; however, the peak is likely
to include contributions from other nitrogen-containing compounds such as carnitine or taurine. Each raw transient, intermediate outputs from
the postprocessing pipeline, and the final fittings, were all visually inspected for potential errors.
Across all spectra, the SNR of each peak was estimated by taking the ratio of the peak height in a 10-Hz exponentially apodised spectrum
(matched filtering) to the SD of the noise extracted from the Fourier Transform of the last 100 points of the free induction decay of the filtered
spectrum.62 Note that care must be taken when comparing spectroscopy SNR values between studies because there are many slightly different
definitions of SNR. The accuracy of the spectral fitting was estimated by calculating the CRLB.63 Due to time constraints, we were unable to run
150 breath-holds for all methods. Thus, to enable a fair comparison, we also randomly selected 12 breath-holds from the STEAM-WET-150 data
to give a 60-measurement subset. For clarity, we refer to these subsampled data as ‘STEAM-WET-60’. This subsampling was performed for
STEAM-WET-150 data in both healthy volunteers and patients.
3.3.2 | Metabolite quantification
Fitted areas for each metabolite A were corrected for T1 and T2 decay and proton density according to:







where SA refers to the uncorrected signal peak integral, SA* refers to the corrected signal peak integral, F1, A and F2, A are T1 and T2 correction fac-
tors and NA is the proton density.
For the phantom, the T1 values were determined to be 0.991 s for the Cr CH3 peak and 1.04 s for water, while the T2 values were determined
to be 321 ms for the Cr CH3 peak and 62.7 ms for water. As there are no published values for T1 and T2 of cardiac metabolites at 3 T, T1 and T2
values from skeletal muscle were used instead. Myocardial lipid T1 and T2 values were taken as the average of intramyocellular and
extramyocellular lipids. The following T1 values were used: 0.459 s for the lipid methylene peak
64; 1.73 s for the Cr CH3 peak
49; 1.37 s for Cho49;
and 1.64 s for water.49 For T2 correction, the following T2 values were used: 78 ms for the lipid methylene peak
64; 177 ms for the Cr CH3 peak
49;
134 ms for Cho49; and 35 ms for water.65
For in vivo acquisitions, Cr and Cho concentrations were calculated in μmol per gram of wet tissue (μmol/g) according to: A½ =SA
Swater × water½ . The concentration of pure water was taken to be 55.5 mol/L and the myocardial tissue was assumed to contain 72.7% water by
weight.51 Myocardial lipid content is represented by the corrected ratio of the lipid methylene peak (1.28 ppm) area to the unsuppressed water
peak area, expressed as a percentage.3
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3.3.3 | Statistical analysis
Sequence performance was assessed by comparing SNR, CRLB and linewidths of the three main metabolite peaks: lipid methylene peak, Cr CH3
peak and Cho peak. The values were described using medians and interquartile ranges, and paired Wilcoxon signed-rank tests (two-tailed) were
conducted across all possible pairings for SNR and CRLB in healthy volunteers. Metabolite concentrations in both healthy volunteers and patients
were described using means and SDs with outliers identified as points more than three scaled median absolute deviations (MAD) away from the
median and were excluded from the analysis.
Intersubject coefficients of variation (σi2) in metabolites were calculated for healthy volunteers by dividing the SD of the metabolite concen-
trations by the overall mean. Repeatability of STEAM-WET and PRESS-WSC were compared by calculating the intrasubject coefficients of varia-
tion (CV) and coefficients of repeatability (CR) for Cr, Cho and lipid quantification. The intrasubject CV can be calculated by taking the ratio of the
SD of within-subject measurements (i.e. the SD of the difference between measurements 1 and 2, also known as σw2) to the overall mean.66 The






Power calculations were also performed using repeatability data from healthy volunteers with G*Power (version 3.1.9.7; Heinrich Heine
Universitat, Dusseldorf, Germany).68,69 The two-tailed a priori power calculation was performed with the following parameters: test family: ‘t
tests’; and statistical test: ‘means: difference between two dependent means (matched pairs)’. To calculate the number of subjects needed to
determine statistical significance (power = 95%, α = 0.05) for a 20% change in concentration for each metabolite for STEAM-WET-150
(150 meas.) and PRESS-WSC (60 meas.), the ‘mean of difference’ was set to 20% of the mean concentration and the ‘SD of difference’ was set
to be the SD of within-subject measurements (σw2).
Lastly, unpaired Student's t-tests (two-tailed, equal variance assumed) were conducted to analyse the differences in metabolite concentra-
tions between healthy volunteers and patients. The metabolite concentrations in healthy volunteers were averaged across both sessions.
4 | RESULTS
4.1 | Phantom study
The correlation between the measured and actual Cr concentration in the phantom for the four sequences is shown in Figure 3. An anomalous
point was identified for PRESS-WET and was subsequently excluded. All correlations had R2 ≥ 0.96 and the slopes of the linear regression lines
(β) ranged from 0.93 to 1.08. The root-mean-squared errors (RMSEs) in concentration measurements for each sequence were 3.51 mmol/L for
PRESS-WET, 7.48 mmol/L for STEAM-WET, 6.15 mmol/L for PRESS-WSC and 6.15 mmol/L for STEAM-WSC. SNR and CRLB values are shown
in Table S2.
4.2 | Sequence comparison in healthy volunteers
Figure 4 shows the four spectra acquired from one healthy volunteer: STEAM-WET-150, STEAM-WET-60, STEAM-WSC and PRESS-WSC.
SNR and CRLB values are shown in Figure 5 for healthy volunteers. The metabolite concentrations for all healthy volunteers and patients are
presented in Table 1, while SNR, CRLB and linewidths are presented in Table S3. The SNR for all three metabolites decreased between STEAM-
WET-150 and STEAM-WET-60 with p-values of less than 0.01 for lipid, less than 0.03 for Cr and less than 0.04 for Cho. On the other hand,
despite being acquired in less than half the scan time, PRESS-WSC showed no significant decrease in SNR for all peaks compared with STEAM-
WET-150. The CRLB values also followed these trends. CRLB increased (i.e. there was worse fit precision) when the number of measurements
was decreased from STEAM-WET-150 to STEAM-WET-60 as expected. Yet with only 60 measurements, the PRESS-WSC sequence gave the
lowest CRLB values (best fit precision) for all metabolites.
Lastly, randomisation of the choice of breath-holds for STEAM-WET-60 did not have any significant effects on SNR, CRLB or linewidths
(Figure S4).
4.3 | Metabolite concentrations in healthy volunteers
Myocardial metabolite concentrations in both healthy volunteers and the patient group are shown in Figure 6. In healthy volunteers, the average
fat fraction measured with STEAM-WET-150 was 0.30% ± 0.11%, and with PRESS-WSC it was 0.30% ± 0.15% (p = 0.78); the average Cr concen-
tration measured with STEAM-WET-150 was 29.6 ± 7.0 μmol/g, and with PRESS-WSC it was 31.5 ± 3.1 μmol/g (p = 0.76); and the average Cho
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F IGURE 4 Spectra from a single volunteer comparing all four protocols tested in the volunteer study
F IGURE 3 Correlation of measured creatine (Cr) concentration and the actual Cr concentration in each phantom compartment measured
with A, PRESS-WSC, B, STEAM-WET, C, PRESS-WSC and D, STEAM-WSC. An anomalous point in A has been identified and labelled using a
black cross. This point was subsequently excluded from data analysis. RMSE, root-mean-squared error
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F IGURE 5 Comparision of Cramér-Rao lower bounds (CRLB) and signal-to-noise ratio (SNR) across all four protocols tested in the volunteer
study for A and D, lipids, B and E, creatine and C and F, choline. The black cross and the attached whiskers represent the median and the
interquartile across all healthy volunteers. For each plot, Wilcoxon signed-rank tests were conducted across all six possible pairs and all significant
p-values (p ≤ 0.05) are shown
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concentration measure with STEAM-WET-150 was 7.9 ± 6.7 μmol/g, and with PRESS-WSC it was 8.3 ± 4.4 μmol/g (p = 0.40). There were no sig-
nificant differences in any of the reported fat fractions or metabolite concentrations between the two sequences.
4.4 | Repeatability in healthy volunteers
Repeatability results are shown in Table 2 and Bland–Altman plots in Figure 7. For lipid quantification, the CR values are comparable for both
sequences, with CR being 0.22% for STEAM-WET-150 and 0.24% for PRESS-WSC (60 meas.). For both Cr and Cho, PRESS-WSC showed
improved performance. The CR for Cr was 4.19 μmol/g for PRESS-WSC and 15.1 μmol/g for STEAM-WET-150. A similar improvement was seen
for Cho, with CR being 1.92 μmol/g for PRESS-WSC and 3.2 μmol/g for STEAM-WET-150.
As an illustration of the power of 3-T 1H-MRS to assess Cr and/or Cho in clinical studies, Table 3 compares the calculated sample sizes
needed to detect a 20% change in metabolite levels for paired and independent studies for both sequences. Sample sizes for independent studies
are reported as the numbers of participants per group, assuming that only 60% of subjects have quantifiable spectra.
4.5 | Demonstration in patient cohort
All patients completed the examination. In one patient, the number of measurements per breath-hold had to be reduced to four to shorten the
length of the breath-hold. Five patient datasets were discarded as they either had fitted linewidths of less than 2 Hz for any of the metabolites,
F IGURE 6 Comparison of metabolite concentrations and fat fractions in healthy and patient cohort with STEAM-WET-150 (‘o’) and PRESS-
WSC (‘×’) for A, lipids, B, creatine and C, choline against various published literature values. For healthy volunteers, the values are an average
between scan 1 and scan 2 while literature data are taken from the following sources: Rial et al. (α),3 Mahmod et al. (β),73 Nakae et al. (γ)50 and
Gilinder et al. (δ).6 Data from Rial et al. and Mahmod et al. were obtained at 3 T, while Nakae et al. and Gilinder et al. obtained their data at 1.5 T.
For the current study, data points more than 1.5 interquartile ranges above the upper quartile or below the lower quartile are treated as outliers
(denoted in black). The black cross and the attached whiskers represent the mean and the standard deviations across all healthy volunteers. The
p-values from the unpaired Student's t-tests are also provided. AS, aortic stenosis; CHF, chronic heart failure
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which indicates that there was only noise in the relevant spectral region, or because of a CRLB value for the lipid peak of more than 500% in
either of the acquisitions. All five had poor STEAM-WET data; four out of five also had poor PRESS-WSC data.
The remaining eight datasets consisted of seven patients with aortic stenosis with preserved systolic function and one patient suffering from
aortic stenosis with impaired systolic function. Figure 8 shows spectra from a patient compared with those from a healthy volunteer.
TABLE 2 Intersubject coefficient of variation (σi2), intrasubject coefficient of variation (σw2) and coefficient of repeatability for lipids, creatine
and choline quantification in healthy volunteers (n = 10)
Repeatability data in healthy volunteers (n = 10)
Sequence Meas. Lipid Creatine Choline
Intersubject coefficient of variation (σi2) STEAM-WET-150 150 37% 24% 86%
PRESS-WSC 60 52% 10% 53%
Intrasubject coefficient of variation (σw2) STEAM-WET-150 150 26% 21% 23%
PRESS-WSC 60 19% 5% 6%
Coefficient of repeatability STEAM-WET-150 150 0.22% 15.1 μmol/g 3.20 μmol/g
PRESS-WSC 60 0.24% 4.19 μmol/g 1.92 μmol/g
F IGURE 7 Bland–Altman plots: A, for lipids with STEAM-WET-150 (coefficient of repeatability [CR] = 0.22%) and PRESS-WSC
(CR = 0.24%); B, for creatine with STEAM-WET-150 (CR = 15.1 μmol/g) and PRESS-WSC (CR = 4.19 μmol/g); and C, for choline with STEAM-
WET-150 (CR = 3.2 μmol/g) and PRESS-WSC (CR = 1.92 μmol/g). The mean difference and the limits of agreement are shown. Data points more
than 1.5 interquartile ranges above the upper quartile or below the lower quartile are treated as outliers (coloured black)
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For the patient cohort, the average fat fractions were 0.48% ± 0.51% when measured with STEAM-WET-150, and 0.25% ± 0.19% when
measured with PRESS-WSC; average Cr concentrations were 8.0 ± 2.3 μmol/g when measured with STEAM-WET-150, and 9.3 ± 6.0 μmol/g
when measured with PRESS-WSC; while average Cho concentrations were 4.6 ± 3.2 μmol/g when measured with STEAM-WET-150, and
3.9 ± 3.2 μmol/g when measured with PRESS-WSC. There were no significant differences in the reported fat fraction or metabolite concentra-
tions between the two sequences.
When comparing the patient cohort with healthy volunteers, there were no significant changes in lipid levels for both sequences (p = 0.26 for
STEAM-WET-150 and p = 0.94 for PRESS-WSC), but significant decreases in Cr levels were observed in the patient group compared with healthy
volunteers for both sequences (p = 0.03 for STEAM-WET-150 and p < 0.01 for PRESS-WSC). The average Cho levels were also lower in the
patient group than in healthy volunteers but these changes were not significant (p = 0.23 for STEAM-WET-150 and p = 0.06 for PRESS-WSC).
TABLE 3 Power calculations shows
the number of subjects (N) needed to
determine statistical significance
(power = 95%, α = 0.05) for a 20%
change in concentration for each
metabolite using STEAM-WET-150 (150
measurements) and PRESS-WSC (60
measurements). The calculations assume
that only 60% of the subjects have
quantifiable spectra
STEAM-WET-150 PRESS-WSC
No. measurements 150 60
Scan duration 30 min 10 min
Numbers needed for paired studies assuming 60% ‘success’ rate in acquisition




F IGURE 8 Spectra from a healthy volunteer (left, both A and C) compared with that of a patient (right, both B and D) suffering from aortic
stenosis. The spectra were acquired with PRESS-WSC in a healthy volunteer (A) and a patient (B), and with STEAM-WET-150 in a healthy
volunteer (C) and a patient (D). All spectra are scaled by the corresponding water peak amplitude. A decrease in creatine (Cr) is seen between
these pairs
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5 | DISCUSSION
5.1 | Sequence performance
5.1.1 | Phantom
Our phantom results show that all four sequences have the potential to quantify Cr levels in the heart in vivo.
5.1.2 | Healthy volunteers
For in vivo acquisitions in healthy volunteers, it would have been ideal to compare STEAM-WET, PRESS-WET, STEAM-WSC and PRESS-WSC in
a single study with sufficient measurements to get a robust quantitation from all methods. However, due to institutional limits on the duration of
a scan, this was not feasible. Thus, PRESS-WET was excluded based on the results of a preliminary study that compared STEAM-WET and
PRESS-WET in six healthy volunteers, where it showed inferior SNR, CRLB and linewidths in all three metabolites.
In the main in vivo study, PRESS-WSC showed increased fitting accuracy (i.e. lower CRLB values) and improved repeatability compared with
the longer ‘gold standard’ STEAM-WET-150 approach, despite having less than half the number of measurements. These improvements translate
to decreases in the number of subjects that would be needed to detect a specified biological effect on Cr or Cho metabolism, as shown by the
power calculations in Table 3. They also indicate that PRESS-WSC may be a shorter (and hence more patient-friendly) alternative to STEAM-WET
for cardiac 1H-MRS.
PRESS-WSC also outperformed both STEAM-WET and STEAM-WSC in terms of the raw SNR for matched scan durations. It is tempting to
attribute the improvement in SNR seen in PRESS-WSC to the difference in signal intensity between PRESS and STEAM. PRESS acquires a spin-
echo signal that inherently has twice the signal intensity compared with a stimulated echo signal acquired by STEAM and this is clearly illustrated
in the phantom dataset. However, perhaps surprisingly, PRESS-WET showed inferior performance in both SNR and CRLB compared with
STEAM-WET in the preliminary in vivo study (Figure S3). This indicates that SNR is controlled by other factors in vivo, for example, differences in
sensitivity to motion and diffusion effects between the two SVS sequences.
In terms of linewidths, both WSC sequences showed decreases in metabolite linewidths compared with STEAM-WET-150, which could be
due to more accurate frequency and phase corrections based on the larger, narrower residual water peak, rather than a smaller, broader lipid peak.
However, the linewidths achieved using STEAM-WSC sequence are on average lower compared with PRESS-WSC. This could be considered as
surprising because PRESS-WSC was regarded as superior to STEAM-WSC when assessed with other measures of spectral quality (e.g. SNR, CRLB
and repeatability). We observed a similar trend between STEAM-WET and PRESS-WET in our preliminary experiment, thus, we hypothesise that
the difference in linewidth could be due to the differences in the STEAM and PRESS sequences. For example, PRESS had a longer TE, which
would increase sensitivity to small motion effects, and PRESS has 180 pulses that may show more slice edge effects than the 90 pulses in
STEAM (with a consequent increase in true voxel size, and hence in linewidth). There are also more complex factors in vivo that might have con-
tributed to the final differences, such as bulk motion and diffusion effects, which will need to be further investigated to fully understand this sur-
prising trend.
Across all in vivo acquisitions, the bandwidth of water-suppression pulses in WSC was larger (65 Hz or 0.5 ppm) than that for WET (50 Hz or
0.4 ppm). This slightly larger bandwidth was determined through empirical observation in a series of pilot experiments. We suspect that the need
for increased water-suppression bandwidth arises because the WSC module needs to either invert or not invert the water. If the water peak drifts
in some transients out of the water-suppression bandwidth, then this can lead to distorted lineshapes that are not fully cancelled during the WSC
postprocessing.
This increased water-suppression bandwidth means that care should be taken when quantifying metabolites with peaks close to water
(e.g. the methylene peak of Cr at 3.9 ppm). It is possible that those peaks might be partially suppressed in the presence of severe shot-to-
shot frequency drifts. In the current study, to avoid this potential issue, we only used the peak amplitude of the Cr methyl group at
3.0 ppm for cardiac Cr quantification, and not the Cr methylene peak at 3.9 ppm. Furthermore, we note that there is no significant differ-
ence in the closer Cho signal at 3.2 ppm between PRESS-WSC and STEAM-WET in our study, suggesting that this effect is not of
concern here.
Another possible factor that affects metabolite quantification is the lack of preparation scans in our protocol. Although preparation scans
ensure that a steady state is reached before signal acquisition, they also lengthen the duration of each breath-hold. A quick calculation using liter-
ature T1 values and nominal flip angles shows that the error in quantification due to the slightly higher signal in the first transient is very small,
accounting for percentage differences smaller than 0.75% for Cr CH3 and 2.2% for Cho. These potential errors are modest compared with other
sources of error in the fitted amplitudes and can be neglected.
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5.1.3 | Patient cohort
In the patient cohort, PRESS-WSC also showed comparable fitting accuracy compared with STEAM-WET-150. In just 60 measurements, PRESS-
WSC showed an average increase of a mere 2% in CRLB values compared with 150 measurements of STEAM-WET-150 (averaging for lipids, Cr
and Cho). The benefits of using PRESS-WSC over STEAM-WET become more obvious when comparing PRESS-WSC with STEAM-WET-60,
where PRESS-WSC delivered an average decrease of 28% in CRLB values and of 18% in linewidths.
STEAM-WET-150 and PRESS-WSC both gave spectra with acceptable quality in all healthy volunteer scans. Yet, in patients, STEAM-WET-
150 only gave acceptable spectra for quantitative analysis in eight out of the 13 patients scanned. PRESS-WSC made a small improvement in this
respect with one more patient having analysable data quality despite the much reduced scan duration. Nevertheless, we are continuing to explore
ways to achieve full robustness in patients as well as in healthy volunteers. We believe the underlying issues are not sequence-specific but include
the familiar issues of heart rate variability, body habitus, compliance with breath holding, age and MR scan familiarity, etc.
5.1.4 | Repeatability
We showed that in less than half the scan duration time (60 vs 150 measurements, or 30 vs 10 breath-holds), PRESS-WSC greatly improves
intrasubject repeatability for the quantification of Cr and Cho, and that it maintains repeatability for lipids (Figure 7) compared with STEAM-WET.
For the repeatability of lipid quantification, Rial et al. reported an intrasubject CV of 19% using a STEAM sequence with breath-holding at
3 T.3 There have also been a number of previous studies published at 1.5 T using gating methods. Szczepaniak et al. reported an intrasubject CV
of 19% using a respiratory gating,70 and Felblinger et al. reported an intrasubject CV of 13% using a double cardiac and respiratory gating
method.71 Our results for PRESS-WSC in healthy volunteers (i.e. an intrasubject CV of 19%) are in good agreement with these reports.
Felblinger et al. also reported intersubject and intrasubject variabilities in cardiac concentrations of Cr and Cho (labelled there as ‘TMA’). In
their study, using a double-triggered PRESS sequence at 1.5 T, they found the intersubject/intrasubject variability for Cr to be 16%/10% and for
Cho to be 56%/9%.71 Similarly, Nakae et al. reported a CV of 7.4% in repeated Cr measurements of eight volunteers using a free breathing PRESS
sequence at 1.5 T with cardiac gating.72 These values are similar to ours for PRESS-WSC; however, our STEAM-WET-150 protocol yielded higher
intersubject/intrasubject variability values for both metabolites.
From both the Bland–Altman plots (Figure 7) and the CR, it can be seen that the lipid repeatability is differently influenced compared with Cr
and Cho. Possible explanations for this include that the lipid peak is influenced by J-coupling. The difference in J-coupling evolution with different
TEs could account for some of the difference in the repeatability changes. Alternatively, because the heart is surrounded by a layer of epicardial
fat, inconsistent diaphragm positions between breath-holds and patient motion could perhaps result in some spectral transients being contami-
nated by epicardial fat.
5.1.5 | Simplicity of implementation
We note in passing that many of the prior studies in cardiac Cr and Cho quantitation have used relatively complicated motion compensation strat-
egies. Our approach has a benefit that it is straightforward to implement because the only sequence modifications are small alterations to the
water suppression module. Other changes are implemented in off-scanner reconstruction tools, which are simpler to alter. Therefore, even where
our repeatability is comparable with some prior studies, this simplicity of implementation is a pragmatic benefit of the WSC approach.
5.2 | Metabolite quantification and changes in patient cohort
In both healthy volunteers and patients, the measured fat fractions and metabolite concentrations did not differ significantly between STEAM-
WET and PRESS-WSC. Both sequences also gave absolute myocardial Cr and Cho concentrations and fat fractions that were similar to values
from the other sequences and from previous studies.4,6,50,51,71
There was no significant difference in myocardial lipid concentrations between patients and controls. The results were 0.30% ± 0.11% in
healthy controls and 0.48% ± 0.51% in patients when measured with STEAM-WET-150 (p = 0.26), and 0.30% ± 0.15% in healthy controls and
0.25% ± 0.19% in patients when measured with PRESS-WSC (p = 0.94). This was unexpected,73 however, Marfella et al.74 reported that lipid con-
tents are significantly higher in aortic stenosis patients with metabolic syndromes than in those without metabolic syndromes. Although none of
our patients had diabetes mellitus, insulin resistance is a known correlate of heart failure,75 so it is likely that our cohort consisted of a mixture of
the two groups, which would be expected to attenuate differences in observed lipid concentration vs healthy volunteers.
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There are few reports on myocardial Cr levels in heart disease. For healthy myocardium, Nakae et al. reported Cr concentrations measured at
1.5 T to be 27.6 ± 4.1 μmol/g51 and Bottomley et al. reported 28 ± 6 μmol/g.76 This is in close agreement with the values we measured in healthy
volunteers (29.6 ± 7.0 μmol/g when measured with STEAM-WET-150 and 31.5 ± 3.1 μmol/g when measured with PRESS-WSC). Nakae et al.
later studied patients suffering from congestive heart failure due to dilated or hypertrophic cardiomyopathy and found a reduction in myocardial
Cr concentrations of 12.5 μmol/g50 (i.e. a 15.5 μmol/g or 45% reduction). The CR of Cr concentration measured with our PRESS-WSC (60 meas.
over 10 breath-holds, CR = 4.19 μmol/g) is roughly one third of this reduction, while that of STEAM-WET-150 (CR = 15.1 μmol/g) is comparable
with the reduction, suggesting that the PRESS-WSC approach is better suited to assessing Cr depletion. In our patient cohort, we observed a sig-
nificant decrease in Cr concentrations in patients vs volunteers with an average reduction of 21.9 μmol/g across the two sequences. Despite the
small cohort scanned in this study, these findings suggest that PRESS-WSC, with its improved repeatability, is a better choice for assessing biolog-
ically relevant changes in Cr concentration than STEAM-WET.
In a study conducted at 1.5 T by Gillinder et al., the myocardial Cho water ratio was 0.24% ± 0.28% before any corrections.6 By correcting for
relaxation and proton density, this result of Gillinder et al. corresponds to a myocardial Cho concentration of 9.6 ± 11.1 μmol/g, which is in line
with our findings of 7.9 ± 6.7 μmol/g with STEAM-WET-150 and 8.3 ± 4.4 μmol/g with PRESS-WSC. Fillmer et al. have also recently quantified
TMA-containing compounds in the myocardium at 3 T (i.e. what we refer to as ‘choline’). They reported a mean TMA to Cr ratio of 0.79 before
any corrections.8 After correcting for relaxation and proton density, the Cho to Cr ratio (SCho*/SCr*) reported by them would be 0.21, which again
is similar to our results of 0.27 for STEAM-WET-150 and 0.26 for PRESS-WSC.
We compare total Cho content in patients with aortic stenosis vs volunteers for the first time. The small sample size in the study means that
it is impossible to draw any statistically significant conclusions about the variations of total Cho between healthy and patient cohorts at this point,
but our work demonstrates the feasibility of 1H-MRS as a clinical tool with which to relate variations in myocardial Cho concentration with varia-
tions in myocardial performance.
Recently, a number of studies have linked dietary Cho intake to cardiovascular diseases in animal models.77 Human studies to investigate this
are more complex due to the significant influence of the intestinal microflora78; there is no general agreement yet on the influence of dietary Cho
intake on the incidence of cardiovascular diseases.79–83 However, preclinical evidence suggests that Cho given as an injection has cardi-
oprotective effects in rat models, including reducing postischaemia reperfusion injuries84 and slowing the progression of hypertension,85 and the
whole-blood Cho level has been identified as a promising biomarker in acute coronary syndrome.86,87 However, most of these studies focused on
dietary Cho intake and/or supplements79 without measuring any direct changes in Cho concentration in the heart. With emerging research aiming
to modulate the cholinergic system and thereby target heart disease,88,89 1H-MRS is a valuable tool for direct measurement of myocardial Cho
in vivo.
5.3 | Future works
In our analysis, we used relaxation times measured in skeletal muscles for quantifying cardiac metabolites. Although a previous imaging study has
shown that T1 and T2 values for heart and skeletal muscles are very similar at both 1.5 and 3 T,
90 we believe that the accuracy in metabolite quan-
tification could be improved by using relaxation values measured directly in the human heart at 3 T.
We also noted that the performance gains for PRESS-WSC were more modest in our patient cohort than in volunteers. In a future study, we
intend to further optimise the WSC module. For example, it may be advantageous to simply cycle the water signal by 180 on alternate transients
without adding the other water-suppression pulses in what would be a purely ‘water-cycled’ MRS method analogous to ‘metabolite-cycled’
methods. It could also be possible to reduce the spacing between water-suppression pulses or to remove the first 90 pulse in the WSC module
to make the PRESS-WSC acquisition fit more easily into the shorter diastole seen in high heart-rate, arrhythmic patients, like those we scanned in
the current study.
We observed decreases in both Cr and Cho levels in the patient group compared with healthy volunteers. However, we only had a limited
study size to provide pathophysiology-related conclusions. Future studies including more patients with aortic or mitral stenosis are required to
gain a better insight into the biochemical changes in the myocardium associated with this diseased state.
6 | CONCLUSIONS
We have shown that a water-suppression cycled PRESS sequence improves performance and repeatability in measuring cardiac metabolites
(lipids, Cr, Cho) relative to the vendor's standard STEAM and PRESS sequences at 3 T. We quantified cardiac Cr and Cho in a 10–breath-hold pro-
tocol, which was robust in healthy volunteers. Lastly, in patients with severe symptomatic valvular heart disease listed for clinically indicated valve
replacement surgery, we were able to detect changes in cardiac metabolites (Cr, Cho, lipids) in a third of the time using PRESS-WSC compared
with the vendor's STEAM-WET sequence.
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ENDNOTE
* The peak we refer to as ‘choline’ for brevity may also contain taurine and carnitine. It is denoted by some authors as the ‘trimethylammonium (TMA) con-
taining compounds’ peak.
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